January 19th, 2012
Are We Ready to Stop Treating Cholesterol Levels and Start Treating Risk?
Harlan M. Krumholz, MD, SM
With the advent of ATPIV, should we stick with determining treatment based on LDL levels or is time for a new paradigm based on a more nuanced understanding of risk?
NEJM Journal Watch — Recent Cardiology Articles- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy